A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
| Autor: | Türeci, O. *, Sahin, U., Schulze-Bergkamen, H., Zvirbule, Z., Lordick, F., Koeberle, D., Thuss-Patience, P., Ettrich, T., Arnold, D., Bassermann, F., Al-Batran, S.E., Wiechen, K., Dhaene, K., Maurus, D., Gold, M., Huber, C., Krivoshik, A., Arozullah, A., Park, J.W., Schuler, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2019 30(9):1487-1495 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|